Abstract
IL-6 is an autocrine growth factor for U266 myeloma cells and their growth is inhibited by IFN-alpha or IL-6 mAb. We asked, therefore, whether IFN-alpha-induced growth inhibition involved IL-6. IFN-alpha and mAb against IL-6, the IL-6R alpha-(gp80) or beta-chain (gp130) potently inhibited U266 cells. Remarkably, this effect occurred despite IFN-alpha-augmented secretion of endogenous IL-6. However, examining the IL-6R revealed that IFN-alpha drastically curtailed expression of the IL-6R alpha- and beta-chain. This effect occurred on two different levels (protein and mRNA) and by two different mechanisms (directly and indirectly through IL-6). First, IFN-alpha, but not IL-6, greatly decreased gp80 and, to a lesser extent, gp130 mRNA levels which resulted in a loss of IL-6 binding sites. Second, IFN-alpha-induced IL-6 predominantly down-regulated membrane-bound gp130. IFN-alpha-mediated decrease of gp80 levels was not detected on IL-6-independent myeloma (RPMI 8226) or myeloid cells (U937). We conclude that IFN-alpha inhibited IL-6-dependent myeloma cell growth by depriving U266 cells of an essential component of their autocrine growth loop, a functional IL-6R.
Full text
PDF![2317](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/f01a14686c7b/jcinvest00490-0147.png)
![2318](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/2dc172715d59/jcinvest00490-0148.png)
![2319](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/80bf535264a2/jcinvest00490-0149.png)
![2320](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/e3800c3085cc/jcinvest00490-0150.png)
![2321](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/d35d75a5e777/jcinvest00490-0151.png)
![2322](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/f478b9fa41db/jcinvest00490-0152.png)
![2323](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/7b491c97a1be/jcinvest00490-0153.png)
![2324](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/51f19a94ba39/jcinvest00490-0154.png)
![2325](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03b/330060/92647df9068c/jcinvest00490-0155.png)
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexanian R., Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994 Feb 17;330(7):484–489. doi: 10.1056/NEJM199402173300709. [DOI] [PubMed] [Google Scholar]
- Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood. 1989 May 15;73(7):1915–1924. [PubMed] [Google Scholar]
- Avvisati G., Mandelli F. The role of interferon-alpha in the management of myelomatosis. Hematol Oncol Clin North Am. 1992 Apr;6(2):395–405. [PubMed] [Google Scholar]
- Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood. 1989 Mar;73(4):865–879. [PubMed] [Google Scholar]
- Bataille R., Jourdan M., Zhang X. G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989 Dec;84(6):2008–2011. doi: 10.1172/JCI114392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bauer J., Bauer T. M., Kalb T., Taga T., Lengyel G., Hirano T., Kishimoto T., Acs G., Mayer L., Gerok W. Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression in human hepatocytes. J Exp Med. 1989 Nov 1;170(5):1537–1549. doi: 10.1084/jem.170.5.1537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med. 1989 Aug 1;170(2):613–618. doi: 10.1084/jem.170.2.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Biondi A., Rossi V., Bassan R., Barbui T., Bettoni S., Sironi M., Mantovani A., Rambaldi A. Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood. 1989 Apr;73(5):1279–1284. [PubMed] [Google Scholar]
- Brakenhoff J. P., Hart M., De Groot E. R., Di Padova F., Aarden L. A. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. J Immunol. 1990 Jul 15;145(2):561–568. [PubMed] [Google Scholar]
- Brenning G., Jernberg H., Gidlund M., Sjöberg O., Nilsson K. The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline. Scand J Haematol. 1986 Oct;37(4):280–288. doi: 10.1111/j.1600-0609.1986.tb02313.x. [DOI] [PubMed] [Google Scholar]
- Dunbar C. E., Browder T. M., Abrams J. S., Nienhuis A. W. COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth. Science. 1989 Sep 29;245(4925):1493–1496. doi: 10.1126/science.2789432. [DOI] [PubMed] [Google Scholar]
- Duperray C., Klein B., Durie B. G., Zhang X., Jourdan M., Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G. Phenotypic analysis of human myeloma cell lines. Blood. 1989 Feb;73(2):566–572. [PubMed] [Google Scholar]
- Faltynek C. R., Princler G. L., Gusella G. L., Varesio L., Radzioch D. A functional protein kinase C is required for induction of 2-5A synthetase by recombinant interferon-alpha A in Daudi cells. J Biol Chem. 1989 Aug 25;264(24):14305–14311. [PubMed] [Google Scholar]
- Faltynek C. R., Princler G. L. Modulation of interferon-alpha and interferon-gamma receptor expression during T-lymphocyte activation and proliferation. J Interferon Res. 1986 Dec;6(6):639–653. doi: 10.1089/jir.1986.6.639. [DOI] [PubMed] [Google Scholar]
- Fiedler W., Weh H. J., Suciu E., Wittlief C., Stocking C., Hossfeld D. K. The IL-6 gene but not the IL-6 receptor gene is occasionally rearranged in patients with multiple myeloma. Leukemia. 1990 Jul;4(7):462–465. [PubMed] [Google Scholar]
- Freeman G. J., Freedman A. S., Rabinowe S. N., Segil J. M., Horowitz J., Rosen K., Whitman J. F., Nadler L. M. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989 May;83(5):1512–1518. doi: 10.1172/JCI114046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goldstein J. L., Anderson R. G., Brown M. S. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature. 1979 Jun 21;279(5715):679–685. doi: 10.1038/279679a0. [DOI] [PubMed] [Google Scholar]
- Hata H., Xiao H., Petrucci M. T., Woodliff J., Chang R., Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood. 1993 Jun 15;81(12):3357–3364. [PubMed] [Google Scholar]
- Herrmann F., Andreeff M., Gruss H. J., Brach M. A., Lübbert M., Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood. 1991 Oct 15;78(8):2070–2074. [PubMed] [Google Scholar]
- Heslop H. E., Bianchi A. C., Cordingley F. T., Turner M., Chandima W., De Mel C. P., Hoffbrand A. V., Brenner M. K. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990 Dec 1;172(6):1729–1734. doi: 10.1084/jem.172.6.1729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990 Dec 21;63(6):1149–1157. doi: 10.1016/0092-8674(90)90411-7. [DOI] [PubMed] [Google Scholar]
- Hirata Y., Taga T., Hibi M., Nakano N., Hirano T., Kishimoto T. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. J Immunol. 1989 Nov 1;143(9):2900–2906. [PubMed] [Google Scholar]
- Jernberg-Wiklund H., Pettersson M., Carlsson M., Nilsson K. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia. 1992 Apr;6(4):310–318. [PubMed] [Google Scholar]
- Jernberg-Wiklund H., Pettersson M., Nilsson K. Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol. 1991 Apr;46(4):231–239. doi: 10.1111/j.1600-0609.1991.tb00546.x. [DOI] [PubMed] [Google Scholar]
- Jernberg H., Pettersson M., Kishimoto T., Nilsson K. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia. 1991 Mar;5(3):255–265. [PubMed] [Google Scholar]
- Jourdan M., Zhang X. G., Portier M., Boiron J. M., Bataille R., Klein B. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol. 1991 Dec 15;147(12):4402–4407. [PubMed] [Google Scholar]
- Kawano M. M., Huang N., Harada H., Harada Y., Sakai A., Tanaka H., Iwato K., Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993 Jul 15;82(2):564–570. [PubMed] [Google Scholar]
- Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
- Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., Tanabe O., Kuramoto A. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood. 1989 Jun;73(8):2145–2148. [PubMed] [Google Scholar]
- Klein B., Wijdenes J., Zhang X. G., Jourdan M., Boiron J. M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991 Sep 1;78(5):1198–1204. [PubMed] [Google Scholar]
- Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989 Feb;73(2):517–526. [PubMed] [Google Scholar]
- Lang R. A., Burgess A. W. Autocrine growth factors and tumourigenic transformation. Immunol Today. 1990 Jul;11(7):244–249. doi: 10.1016/0167-5699(90)90098-t. [DOI] [PubMed] [Google Scholar]
- Lasfar A., Wietzerbin J., Billard C. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur J Immunol. 1994 Jan;24(1):124–130. doi: 10.1002/eji.1830240119. [DOI] [PubMed] [Google Scholar]
- Levy Y., Tsapis A., Brouet J. C. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest. 1991 Aug;88(2):696–699. doi: 10.1172/JCI115355. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lu C., Kerbel R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993 Mar;120(5):1281–1288. doi: 10.1083/jcb.120.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ludwig H., Nachbaur D. M., Fritz E., Krainer M., Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991 Jun 15;77(12):2794–2795. [PubMed] [Google Scholar]
- Lütticken C., Wegenka U. M., Yuan J., Buschmann J., Schindler C., Ziemiecki A., Harpur A. G., Wilks A. F., Yasukawa K., Taga T. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 1994 Jan 7;263(5143):89–92. doi: 10.1126/science.8272872. [DOI] [PubMed] [Google Scholar]
- Müllberg J., Schooltink H., Stoyan T., Günther M., Graeve L., Buse G., Mackiewicz A., Heinrich P. C., Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993 Feb;23(2):473–480. doi: 10.1002/eji.1830230226. [DOI] [PubMed] [Google Scholar]
- Müller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., Harpur A. G., Barbieri G., Witthuhn B. A., Schindler C. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature. 1993 Nov 11;366(6451):129–135. doi: 10.1038/366129a0. [DOI] [PubMed] [Google Scholar]
- Nesbitt J. E., Fuller G. M. Differential regulation of interleukin-6 receptor and gp130 gene expression in rat hepatocytes. Mol Biol Cell. 1992 Jan;3(1):103–112. doi: 10.1091/mbc.3.1.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nesbitt J. E., Fuller G. M. Dynamics of interleukin-6 internalization and degradation in rat hepatocytes. J Biol Chem. 1992 Mar 25;267(9):5739–5742. [PubMed] [Google Scholar]
- Nilsson K., Bennich H., Johansson S. G., Pontén J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol. 1970 Oct;7(4):477–489. [PMC free article] [PubMed] [Google Scholar]
- Nishimoto N., Ogata A., Shima Y., Tani Y., Ogawa H., Nakagawa M., Sugiyama H., Yoshizaki K., Kishimoto T. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med. 1994 Apr 1;179(4):1343–1347. doi: 10.1084/jem.179.4.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Okuno Y., Takahashi T., Suzuki A., Fukumoto M., Nakamura K., Fukui H., Koishihara Y., Ohsugi Y., Imura H. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. Exp Hematol. 1992 May;20(4):395–400. [PubMed] [Google Scholar]
- Portier M., Rajzbaum G., Zhang X. G., Attal M., Rusalen C., Wijdenes J., Mannoni P., Maraninchi D., Piechaczyk M., Bataille R. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol. 1991 Jul;21(7):1759–1762. doi: 10.1002/eji.1830210727. [DOI] [PubMed] [Google Scholar]
- Portier M., Zhang X. G., Caron E., Lu Z. Y., Bataille R., Klein B. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood. 1993 Jun 1;81(11):3076–3082. [PubMed] [Google Scholar]
- Schwab G., Siegall C. B., Aarden L. A., Neckers L. M., Nordan R. P. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991 Feb 1;77(3):587–593. [PubMed] [Google Scholar]
- Schwabe M., Zhao J., Kung H. F. Differential expression and ligand-induced modulation of the human interleukin-6 receptor on interleukin-6-responsive cells. J Biol Chem. 1994 Mar 11;269(10):7201–7209. [PubMed] [Google Scholar]
- Sidell N., Taga T., Hirano T., Kishimoto T., Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol. 1991 Jun 1;146(11):3809–3814. [PubMed] [Google Scholar]
- Splawski J. B., McAnally L. M., Lipsky P. E. IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). J Immunol. 1990 Jan 15;144(2):562–569. [PubMed] [Google Scholar]
- Sporn M. B., Roberts A. B. Autocrine growth factors and cancer. 1985 Feb 28-Mar 6Nature. 313(6005):745–747. doi: 10.1038/313745a0. [DOI] [PubMed] [Google Scholar]
- Stahl N., Boulton T. G., Farruggella T., Ip N. Y., Davis S., Witthuhn B. A., Quelle F. W., Silvennoinen O., Barbieri G., Pellegrini S. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science. 1994 Jan 7;263(5143):92–95. doi: 10.1126/science.8272873. [DOI] [PubMed] [Google Scholar]
- Suzuki H., Yasukawa K., Saito T., Goitsuka R., Hasegawa A., Ohsugi Y., Taga T., Kishimoto T. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol. 1992 Aug;22(8):1989–1993. doi: 10.1002/eji.1830220806. [DOI] [PubMed] [Google Scholar]
- Taga T., Narazaki M., Yasukawa K., Saito T., Miki D., Hamaguchi M., Davis S., Shoyab M., Yancopoulos G. D., Kishimoto T. Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10998–11001. doi: 10.1073/pnas.89.22.10998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Velazquez L., Fellous M., Stark G. R., Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992 Jul 24;70(2):313–322. doi: 10.1016/0092-8674(92)90105-l. [DOI] [PubMed] [Google Scholar]
- Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B., Taniguchi T., Hirano T., Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988 Aug 12;241(4867):825–828. doi: 10.1126/science.3136546. [DOI] [PubMed] [Google Scholar]
- Zhang X. G., Bataille R., Jourdan M., Saeland S., Banchereau J., Mannoni P., Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood. 1990 Dec 15;76(12):2599–2605. [PubMed] [Google Scholar]